Biomedicine & Pharmacotherapy, Год журнала: 2024, Номер 182, С. 117772 - 117772
Опубликована: Дек. 18, 2024
Язык: Английский
Signal Transduction and Targeted Therapy, Год журнала: 2024, Номер 9(1)
Опубликована: Июль 5, 2024
Abstract Cancer stem cells (CSCs), a small subset of in tumors that are characterized by self-renewal and continuous proliferation, lead to tumorigenesis, metastasis, maintain tumor heterogeneity. continues be significant global disease burden. In the past, surgery, radiotherapy, chemotherapy were main cancer treatments. The technology treatments develop advance, emergence targeted therapy, immunotherapy provides more options for patients certain extent. However, limitations efficacy treatment resistance still inevitable. Our review begins with brief introduction historical discoveries, original hypotheses, pathways regulate CSCs, such as WNT/β-Catenin, hedgehog, Notch, NF-κB, JAK/STAT, TGF-β, PI3K/AKT, PPAR pathway, their crosstalk. We focus on role CSCs various therapeutic outcomes resistance, including how affect content alteration related molecules, CSCs-mediated clinical value targeting refractory, progressed or advanced tumors. summary, efficacy, method is difficult determine. Clarifying regulatory mechanisms biomarkers currently mainstream idea.
Язык: Английский
Процитировано
85
Critical Reviews in Oncology/Hematology, Год журнала: 2024, Номер 197, С. 104351 - 104351
Опубликована: Апрель 12, 2024
Breast cancer is potentially a lethal disease and leading cause of death in women. Chemotherapy radiotherapy are the most frequently used treatment options. Drug resistance advanced breast limits therapeutic output treatment. The endocrine hormonal imbalance, particularly triple negative HER2 positive cancers. efflux drugs due to p-gp's activity another resistance. resistant protein also contributes significantly. Strategies combat include use nanoparticles target drug delivery by co-delivery chemotherapeutic genes (siRNA miRNA) that help down-regulate causing siRNA specific effectively silences p-gp other proteins chemosensitizers effective overcoming Chemo-sensitizers sensitize cells effects drugs. Novel anti-neoplastic agents such as antibody-drug conjugates mesenchymal stem tools improve response cancer. Similarly, combination photo/thermal ablation with chemotherapy can act overcome In this review, we focus on mechanism nanoparticle-based strategies
Язык: Английский
Процитировано
18
RSC Advances, Год журнала: 2024, Номер 14(20), С. 14017 - 14040
Опубликована: Янв. 1, 2024
Nanotechnology revolutionizes breast cancer treatment by improving drug delivery, overcoming barriers, and reducing side effects. This review highlights its potential superiority over conventional methods, transforming management.
Язык: Английский
Процитировано
13
Molecular Cancer, Год журнала: 2025, Номер 24(1)
Опубликована: Март 20, 2025
Ovarian cancer is one the deadliest disease wherein survival rate very low. Despite of advances in medical sciences, researches are still at stage infancy where patients succumbing to this malignancy. Multidrug resistance, toxicity, mode treatment related issues like catheter complication poises a number challenges scientists worldwide. Novel therapy now thus being focussed sensitive cells more towards treatment. Gold nanoparticles (Au NPs), known for their high biocompatibility, and strong optical magnetic responses, have emerged as promising agents both diagnosis ovarian cancer. Owing physical characteristics, AuNPs may be used adjuvants bioimaging, radiotherapy fluorescence imaging. As result, these characteristics substantially support biological domains. In addition therapeutic potential, Au NPs exhibit surface plasmon resonance (SPR) properties, enhancing imaging techniques early detection tumors. Furthermore, chemical properties such Magnetic Resonance Imaging Properties, X-ray property, Two-photon or multiphoton imaging, Optical coherence tomography (OCT) enhance use diagnosis. This paper highlights targeting potential by has been discussed.
Язык: Английский
Процитировано
1
International Journal of Biological Macromolecules, Год журнала: 2024, Номер 272, С. 132888 - 132888
Опубликована: Июнь 1, 2024
Язык: Английский
Процитировано
4
Expert Review of Proteomics, Год журнала: 2025, Номер unknown
Опубликована: Янв. 16, 2025
Objective Our study presents a novel analysis of the oncogenes and tumor suppressor proteins directly modulated by E6/E7 high-risk HPV types 16 18, in colorectal cancer (CRC).
Язык: Английский
Процитировано
0
Future Oncology, Год журнала: 2025, Номер unknown, С. 1 - 21
Опубликована: Фев. 12, 2025
Triple-negative breast cancer (TNBC) presents a formidable global health challenge, marked by its aggressive behavior and significant treatment resistance. This subtype, devoid of estrogen, progesterone, HER2 receptors, largely relies on stem cells (BCSCs) for progression, metastasis, recurrence. BCSCs, characterized their self-renewal capacity resistance to conventional therapies, exploit key surface markers critical signaling pathways like Wnt, Hedgehog, Notch, TGF-β, PI3K/AKT/mTOR Hippo-YAP/TAZ thrive. Their adaptability is underscored mechanisms including drug efflux enhanced DNA repair, contributing poor prognosis high recurrence rates. The tumor microenvironment (TME) further facilitates BCSC survival through complex interactions with stromal immune cells. Emerging therapeutic strategies targeting BCSCs - ranging from immunotherapy nanoparticle-based delivery systems gene-editing technologies aim disrupt these resistant Additionally, innovative approaches focusing exosome-mediated metabolic reprogramming show promise in overcoming chemoresistance. By elucidating the distinct characteristics role TNBC, researchers are paving way novel treatments that may effectively eradicate resilient cells, mitigate ultimately improve patient outcomes. review highlights urgent need targeted address unique biology pursuit more effective interventions TNBC.
Язык: Английский
Процитировано
0
International Journal of Nanomedicine, Год журнала: 2025, Номер Volume 20, С. 3493 - 3525
Опубликована: Март 1, 2025
Human serum albumin (HSA) has emerged as a promising carrier for nanodrug delivery, offering unique structural properties that can be engineered to overcome key challenges in cancer treatment, especially resistance chemotherapy. This review focuses on the cellular uptake of albumin-based nanoparticles and modifications enhance their ability bypass mechanisms, particularly multidrug type 1 (MDR1), by improving targeting cells. In our approach, we integrate chemical albumin, its interactions with cells, surface delivery systems enable those related MDR1, precisely target receptors cells improve treatment efficacy. We discuss while well-established such gp60 gp18/30 are crucial transcytosis, biology remains underexplored, limiting translational potential. Additionally, explore potential emerging targets, cluster differentiation 44 (CD44), (CD36) transferrin receptor TfR1, well advantages using dimeric forms (dHSA) further resistant Drawing from clinical examples, including success albumin-bound paclitaxel (Abraxane) new formulations like Pazenir Fyarro (for Sirolimus), identify gaps current knowledge propose strategies optimize systems. conclusion, nanoparticles, when tailored appropriate modifications, have By enhancing albumin's efficiently deliver therapeutic agents, these carriers represent approach addressing one oncology's most persistent challenges, substantial outcomes.
Язык: Английский
Процитировано
0
Discover Oncology, Год журнала: 2025, Номер 16(1)
Опубликована: Март 22, 2025
Cancer stem cells (CSCs), are a critical subpopulation within tumours, and defined by their capacity for self-renewal, differentiation, tumour initiation. These unique traits contribute to progression, metastasis, resistance conventional treatments like chemotherapy radiotherapy, often resulting in cancer recurrence poor patient outcomes. As such, CSCs have become focal points developing advanced therapies. This review highlights progress CSC-targeted treatments, including chimeric antigen receptor T-cell (CAR-T) therapy, immunotherapy, molecular targeting, nanoparticle-based drug delivery systems. Plant-derived compounds gene-editing technologies, such as clustered regularly interspaced short palindromic repeats (CRISPR), explored potential enhance precision minimize side effects. Metabolic pathways integral CSC survival, mitochondrial dynamics, mitophagy (regulated dynamin-related protein 1 [DRP1] the PINK1/Parkin pathway), one-carbon metabolism, amino acid metabolism (involving enzymes glutaminase (GLS) glutamate dehydrogenase (GDH]), lipid hypoxia-induced metabolic reprogramming mediated hypoxia-inducible factors (HIF-1α HIF-2α), examined therapeutic targets. The adaptability of through autophagy, flexibility, epigenetic regulation metabolites α-ketoglutarate, succinate, fumarate is discussed. Additionally, extracellular vesicles nicotinamide adenine dinucleotide (NAD⁺) identified pivotal redox balance, DNA repair, modifications. Addressing challenges heterogeneity, immune evasion, treatment durability requires interdisciplinary collaboration. Advancing therapies essential overcoming preventing relapse, paving way transformative treatments. underscores importance leveraging innovative technologies fostering collaboration revolutionize treatment.
Язык: Английский
Процитировано
0
International Journal of Biological Macromolecules, Год журнала: 2024, Номер 279, С. 135099 - 135099
Опубликована: Авг. 27, 2024
Язык: Английский
Процитировано
3